Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C32H47F5O3S |
| Molecular Weight | 606.771 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)CC4=CC(O)=CC=C34
InChI
InChIKey=VWUXBMIQPBEWFH-MSCODYEVSA-N
InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26+,27-,28-,29+,30-,41?/m0/s1
Fulvestrant Beta-Isomer, also known as Fulvestrant EP Impurity A. Fulvestrant, sold under the trade name Faslodex among others, is an estrogen receptor antagonist indicated for the treatment of hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID40193748
Created by
admin on Mon Mar 31 21:28:00 GMT 2025 , Edited by admin on Mon Mar 31 21:28:00 GMT 2025
|
PRIMARY | |||
|
71317003
Created by
admin on Mon Mar 31 21:28:00 GMT 2025 , Edited by admin on Mon Mar 31 21:28:00 GMT 2025
|
PRIMARY | |||
|
407577-53-1
Created by
admin on Mon Mar 31 21:28:00 GMT 2025 , Edited by admin on Mon Mar 31 21:28:00 GMT 2025
|
PRIMARY | |||
|
L8HA5DT6RS
Created by
admin on Mon Mar 31 21:28:00 GMT 2025 , Edited by admin on Mon Mar 31 21:28:00 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
